Akari Therapeutics Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy (GA)
NEW YORK and LONDON, Feb. 15, 2023 (GLOBE NEWSWIRE) — Akari…
Bavarian Research Foundation supports the development of an immunosuppressive PASylated antibody fragment to support cardiac xenotransplantation
Munich, September 28, 2022 – A research consortium composed…
Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy
NEW YORK and LONDON, July 28, 2022 (GLOBE NEWSWIRE) -- Akari…